Chairman & CEO
Mr. Dahlhauser has more than 20 years of experience in the commercial application of molecular technologies. He served as Insight Genetics’ Chairman and CEO since the formation of the company in 2007 and was previously the Chairman and CEO of Genetic Assays, Inc., a molecular clinical diagnostics company. Dahlhauser has been a Certified Public Accountant since 1986.
President & COO
Dr. Callaghan has more than 20 years of experience working with start-up and emerging growth technology companies, including as the founder and CEO of companies that were sold to Quebecor World Inc. and Tyco International.
Vice President, Research & Development
Dr. Hout has extensive experience in the fields of molecular biology and molecular diagnostics. Prior to joining Insight Genetics, he served as senior research microbiologist at Biomune in Lenexa, Kansas. Dr. Hout holds a PhD in molecular virology from the University of Kansas Medical Center. He completed postdoctoral work in biochemistry and virology at Vanderbilt University Medical Center.
Scientific Founder & Chief Scientific Officer
Dr. Morris is an internationally recognized physician-scientist and translational investigator whose work focuses on molecular oncology. He was most recently a clinician and researcher at St. Jude Children’s Research Hospital, where his laboratory discovered and characterized a number of oncogenes including NPM-ALK and several other ALK fusion genes. He earned his MD from Louisiana State University, completed an internal medicine residency at the University of Texas Southwestern Health Science Center, and trained in medical oncology at Yale University School of Medicine.
Chief Strategic Adviser
Dr. Chen has broad research and development and merchant banking experience in the life science industry. Before founding Ignatius Transaction Partners, he was a managing director at Burrill & Company. Prior to banking, he led R&D at Roche Diagnostics, Novartis and start-up companies. He received his academic training at the University of Wisconsin and Stanford University.
Chief Technology Officer
Rob Seitz is a seasoned molecular diagnostics professional with extensive experience in business strategy and product development and expertise in lung cancer and breast cancer. Rob was Senior Vice President for Technology Assessment at Clarient, Inc. He also served as CEO and co-founder of Applied Genomics, Inc. (AGI) prior to its acquisition by Clarient. Rob earned his B.S. in chemistry from the University of South Alabama and obtained a M.Div. at Fuller Theological Seminary.